Table 1.
Clinical and molecular characteristics according to miR-3151 expression status in CN-AML patients 60 years of age or older
| Characteristic | Low miR-3151* (n = 90) | High miR-3151* (n = 89) | P† |
|---|---|---|---|
| Age, y | .99 | ||
| Median | 68 | 68 | |
| Range | 60-79 | 60-81 | |
| Sex, n (%) | .88 | ||
| Male | 48 (53) | 49 (55) | |
| Female | 42 (47) | 40 (45) | |
| Race, n (%) | .10 | ||
| White | 79 (88) | 83 (95) | |
| Nonwhite | 11 (12) | 4 (5) | |
| Hemoglobin, g/dL | .47 | ||
| Median | 9.3 | 9.5 | |
| Range | 6.0-11.7 | 6.5-15.0 | |
| Platelet count, × 109/L | .36 | ||
| Median | 60 | 69 | |
| Range | 4-481 | 11-850 | |
| WBC count, × 109/L | .10 | ||
| Median | 26.2 | 38.7 | |
| Range | 1.4-450.0 | 1.1-434.1 | |
| Percentage of blood blasts | .02 | ||
| Median | 65 | 39 | |
| Range | 0-96 | 0-99 | |
| Percentage of BM blasts | .52 | ||
| Median | 70 | 69 | |
| Range | 11-97 | 4-96 | |
| Extramedullary involvement, n (%) | 21 (24) | 24 (28) | .73 |
| NPM1, n (%) | < .001 | ||
| Mutated | 71 (79) | 43 (49) | |
| Wild-type | 19 (21) | 45 (51) | |
| FLT3-ITD, n (%) | 1.00 | ||
| Present | 33 (37) | 33 (38) | |
| Absent | 57 (63) | 55 (63) | |
| CEBPA, n (%) | .83 | ||
| Mutated | 12 (13) | 13 (15) | |
| Single mutated | 7 | 8 | |
| Double mutated | 5 | 5 | |
| Wild-type | 78 (87) | 76 (85) | |
| ELN Genetic Group, n (%)‡ | .05 | ||
| Favorable | 50 (56) | 35 (40) | |
| Intermediate-I | 40 (44) | 52 (60) | |
| RUNX1, n (%) | < .001 | ||
| Mutated | 4 (5) | 19 (24) | |
| Wild-type | 80 (95) | 59 (76) | |
| FLT3-TKD, n (%) | 1.00 | ||
| Present | 7 (8) | 7 (8) | |
| Absent | 82 (92) | 79 (92) | |
| WT1, n (%) | .08 | ||
| Mutated | 3 (3) | 9 (10) | |
| Wild-type | 87 (97) | 79 (90) | |
| TET2, n (%) | .33 | ||
| Mutated | 24 (27) | 30 (35) | |
| Wild-type | 65 (73) | 56 (65) | |
| MLL-PTD, n (%) | .50 | ||
| Present | 3 (5) | 6 (8) | |
| Absent | 63 (95) | 67 (92) | |
| IDH1, n (%) | 1.00 | ||
| R132 mutated | 12 (13) | 10 (11) | |
| V71I mutated | 0 | 1 (1) | |
| Wild-type | 77 (87) | 76 (87) | |
| IDH2, n (%) | .71 | ||
| IDH2 | 20 (22) | 17 (20) | |
| R140 mutated | 20 | 14 | |
| R172 mutated | 0 | 3 | |
| Wild-type | 69 (78) | 70 (80) | |
| ASXL1, n (%) | .13 | ||
| Mutated | 9 (10) | 16 (19) | |
| Wild-type | 79 (90) | 69 (81) | |
| DNMT3A, n (%) | .74 (mut vs wt) | ||
| Mutated | 27 (31) | 29 (35) | |
| R882 | 15 | 19 | .56 (R882 vs wt) |
| Non-R882 | 12 | 10 | 1.00 (non-R882 vs wt) |
| Wild-type | 59 (69) | 55 (65) | |
| ERG expression group, n (%)* | .40 | ||
| High | 42 (58) | 35 (50) | |
| Low | 31 (42) | 35 (50) | |
| BAALC expression group, n (%)* | < .001 | ||
| High | 34 (39) | 56 (66) | |
| Low | 54 (61) | 29 (34) | |
| MN1 expression group, n (%)* | .05 | ||
| High | 18 (37) | 31 (56) | |
| Low | 31 (63) | 24 (44) |
*
The median expression value was used as the cutoff point.
†
P values for categorical variables are from the Fisher exact test; P values for continuous variables are from the Wilcoxon rank-sum test.
‡
The ELN Favorable Genetic Group comprises patients with mutated CEBPA and those with mutated NPM1 without FLT3-ITD; the ELN Intermediate-I Genetic Group includes patients with CEBPA wild-type who are FLT3-ITD–positive and NPM1-mutated, FLT3-ITD–negative and NPM1 wild-type, or FLT3-ITD–positive and NPM1 wild-type.